An interventional study of Pleasant Food Odor Stimulation and Control Environmental Condition in Obesity & Overweight and Insulin Resistance Syndrome, sponsored by Hospices Civils de Lyon. Not yet recruiting at 1 site in France. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-10.
Sponsored by Hospices Civils de Lyon · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies in Obesity by Hospices Civils de Lyon — 11 open to participants now, 12 under way, 1 of them phase 3. Obesity · Hospices Civils de Lyon.
Among the 32 studies in Obesity by Hospices Civils de Lyon, this one is the 21st largest by planned enrollment of the 23 interventional ones that give a count, is one of 4 that started in 2026, is one of 20 with no phase, reaches primary completion later than 6 of the 11 other live ones, and was the 30th registered.
11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.
Browse Obesity studies →11 of the 32 studies in Obesity by Hospices Civils de Lyon are open now, in 1 country. Recruiting first, the newest first:
Hospices Civils de Lyon · Sites in France
Ages 18–75
Hospices Civils de Lyon · Sites in France
Ages 25–65
Hospices Civils de Lyon · Sites in France
Ages 18–70
Hospices Civils de Lyon · Sites in France
Ages 18–65 · Healthy volunteers
Hospices Civils de Lyon · Sites in France
Ages 40–80
By country, each count listing its studies:
Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.
This study: 18 Years to 50 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 67 across 9,043 interventional studies indexed under Obesity.
Median enrollment 70 across the 23 interventional studies, 76 across the 9 observational. Of the 13 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Hospices Civils de Lyon is the lead sponsor of 1,868 studies on the registry; 447 are open to participants now.
4 of the studies in Obesity by Hospices Civils de Lyon that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03516968Phase 3Hospices Civils de LyonMonthly Boluses Versus Daily Doses for Correcting Blood Vitamin D Deficit in Obese Children and Adolescents | 2027-03 |
| NCT06567990Hospices Civils de LyonType 2 DIAbeTes With NAFLD: innOvative Biomarkers of Disease progressioN and clInical outComes | 2027-05-25 |
| NCT07638111Hospices Civils de LyonSENSILINS: Impact of Cephalic Phase Insulin Release Induced by an Environmental Food Odor Stimulus on Glucose Homeostasis According to Insulin Sensitivity Level | 2027-07 |
| NCT07268508Hospices Civils de LyonImpact of a Pro-diversity Gut Microbiota Diet After a Bariatric Surgery on Gut Microbiota, Eating Behaviour and Sensory Function | 2027-11-05 |
Add all 4 to your calendar (.ics) → With an account.
Among the 32 studies in Obesity by Hospices Civils de Lyon, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This single-center, randomized, single-blind, 2-period crossover interventional study will evaluate whether exposure to a pleasant food odor 10 minutes before a 75 g oral glucose tolerance test (OGTT) modifies glucose homeostasis in adults with different metabolic phenotypes. Participants will undergo two experimental conditions in random order: food odor stimulation and control condition without odor, separated by a 4-week washout. The main objective is to quantify the within-subject effect of food odor stimulation on the incremental area under the glucose curve (iAUC) from 0 to 120 minutes during OGTT and to assess whether this effect differs according to metabolic status. Two predefined groups will be enrolled: adults without overweight and without insulin resistance, and adults with class I obesity and low-to-moderate insulin resistance. Secondary objectives include characterization of cephalic phase insulin release (CPIR), C-peptide and GLP-1 responses, glycemic kinetics, associations between CPIR and metabolic responses, and participant acceptability of the test environment and olfactory stimulation. A plasma biobank will be constituted from part of the collected samples for future research.
Recent experimental and translational data suggest that olfactory cues may contribute to metabolic regulation through anticipatory cephalic phase responses. Cephalic phase insulin release (CPIR) is an early preabsorptive insulin response triggered by sensory food-related stimuli before nutrient absorption. Preclinical data generated by the study team suggest that food-odor-induced CPIR involves an olfactory bulb-pancreas axis and may be altered in obesity. The present study is designed to investigate, in humans, whether a pleasant appetitive food odor delivered before glucose ingestion can induce measurable CPIR and improve post-load glucose handling.
The study uses a randomized AB/BA crossover design with two experimental visits after screening and inclusion. During one visit, participants are exposed to prerecorded food odor diffusion using a ScentRealm collar starting at T-10 minutes before ingestion of a 75 g glucose solution at T0. During the control visit, the same testing environment is maintained without odor stimulation. Serial blood sampling is performed before and after glucose ingestion to characterize glucose, insulin, C-peptide, and GLP-1 kinetics. The washout period is 4 weeks (±3 days), partly to align visits within the same menstrual cycle phase in women when applicable. The trial includes 20 adults aged 18 to 50 years: 10 without overweight and insulin-sensitive, and 10 with obesity and low-to-moderate insulin resistance defined using HOMA-IR.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants are exposed to a pleasant appetitive food odor delivered through a ScentRealm collar beginning 10 minutes before ingestion of a 75 g oral glucose load and continuing according to a prerecorded sequence during the metabolic test visit.
Behavioral: Pleasant Food Odor Stimulation · Behavioral: Control Environmental Condition
Participants undergo the same standardized metabolic test visit and OGTT procedures in the same test environment without food odor stimulation.
Behavioral: Pleasant Food Odor Stimulation · Behavioral: Control Environmental Condition
Exposure to an experimentally selected appetitive food odor (madeleine odor) delivered using a programmable ScentRealm collar in a standardized test room beginning at T-10 minutes before OGTT.
Standardized testing environment identical to the experimental visit but without diffusion of the appetitive food odor.
Within-subject difference in glucose incremental area under the curve (iAUC) from 0 to 120 minutes during OGTT
Primary endpoint is the mean within-subject difference between food odor and control conditions in glucose incremental area under the curve from 0 to 120 minutes after oral glucose ingestion. Glucose iAUC will be calculated using the trapezoidal method, baseline-adjusted to glucose at T0. The main analysis will also assess the interaction between condition (odor vs control) and metabolic status (no overweight/insulin-sensitive vs obesity with low-to-moderate insulin resistance). Unit should be specified in the statistical analysis plan according to assay reporting (for example mmol/L×min or mg/dL×min).
Time frame: During each experimental visit, from 0 to 120 minutes after ingestion of the 75 g oral glucose load
Preabsorptive and early post-ingestion insulin iAUC as a measure of cephalic phase insulin release
Incremental area under the curve for insulin during the pre-ingestion and early post-ingestion period (0 to 15 minutes), compared by condition and metabolic status. Additional CPIR-related metrics include latency, peak concentration, slope, and percentage of responders. Unit to specify according to assay output (for example µIU/mL×min or pmol/L×min).
Time frame: From pre-OGTT odor exposure through 15 minutes after glucose ingestion during each experimental visit
Preabsorptive and early post-ingestion C-peptide iAUC
Incremental area under the curve for C-peptide during the pre-ingestion and early post-ingestion period (0 to 15 minutes), compared by condition and metabolic status. Additional metrics include latency, peak concentration, slope, and percentage of responders. Unit to specify according to assay output.
Time frame: From pre-OGTT odor exposure through 15 minutes after glucose ingestion during each experimental visit
Glycemic kinetic response during OGTT - Δmax
Effect of condition and metabolic status on glycemic maximum change from baseline (Δmax)
Time frame: From 0 to 120 minutes after glucose ingestion during each experimental visit
Glycemic kinetic response during OGTT - Time to peak
Effect of condition and metabolic status on the necessary amount of time to reach glycemic peak in minutes
Time frame: From 0 to 120 minutes after glucose ingestion during each experimental visit
Glycemic kinetic response during OGTT - Growth curve slope
Effect of condition and metabolic status on the slope of the glycemic growth curve from baseline
Time frame: From 0 to 120 minutes after glucose ingestion during each experimental visit
Glycemic kinetic response during OGTT - Decay curve slope
Effect of condition and metabolic status on the slope of the glycemic decay curve from the maximum (peak)
Time frame: From 0 to 120 minutes after glucose ingestion during each experimental visit
Glycemic kinetic response during OGTT - ultradian oscillation indices
Effect of condition and metabolic status on ultradian oscillation indices
Time frame: From 0 to 120 minutes after glucose ingestion during each experimental visit
Glycemic kinetic response during OGTT - iAUC (0 to 120 min)
Effect of condition and metabolic status on Incremental Area Under the Curve (IAUC) from 0 to 120 min for glucose
Time frame: From 0 to 120 minutes after glucose ingestion during each experimental visit
Glycemic kinetic response during OGTT - early glucose iAUC (0-30min)
Effect of condition and metabolic status on glucose Incremental Area Under the Curve (IAUC) from 0 to 30 min
Time frame: From 0 to 30 minutes after glucose ingestion during each experimental visit
Glycemic kinetic response during OGTT - late glucose iAUC (30-120 min)
Effect of condition and metabolic status on glucose Incremental Area Under the Curve (IAUC) from 30 to 120 min
Time frame: From 30 to 120 minutes after glucose ingestion during each experimental visit
Hormonal response parameters for insulin during OGTT - iAUC (0-120 min)
Total Incremental Area Under the Curve (iAUC) from 0 to 120 minutes
Time frame: From 0 to 120 minutes after glucose ingestion during each experimental visit
Hormonal response parameters for insulin during OGTT - iAUC (0-30min)
Insulin Incremental Area Under the Curve (IAUC) from 0 to 30 min
Time frame: From 0 to 30 minutes after glucose ingestion during each experimental visit
Hormonal response parameters for insulin during OGTT - iAUC (30-120min)
Insulin Incremental Area Under the Curve (IAUC) from 30 to 120 min
Time frame: From 30 to 120 minutes after glucose ingestion during each experimental visit
Hormonal response parameters for insulin during OGTT - Δmax
The value of the maximum (peak) of the curve relative to the baseline value for insulin
Time frame: From 0 to 120 minutes after glucose ingestion during each experimental visit
Hormonal response parameters for insulin during OGTT - Time to peak
Necessary amount of time for insulin to reach peak in minutes
Time frame: From 0 to 120 minutes after glucose ingestion during each experimental visit
Hormonal response parameters for insulin during OGTT - Growth curve slope
Slope of the insulin growth curve from baseline
Time frame: From 0 to 120 minutes after glucose ingestion during each experimental visit
Hormonal response parameters for insulin during OGTT - Decay curve slope
Slope of the insulin decay curve from the maximum (peak)
Time frame: From 0 to 120 minutes after glucose ingestion during each experimental visit
Hormonal response parameters for C-peptide during OGTT - iAUC (0-120min)
C-peptide Incremental Area Under the Curve (IAUC) from 0 to 120 min
Time frame: From 0 to 120 minutes after glucose ingestion during each experimental visit
Hormonal response parameters for C-peptide during OGTT - iAUC (0-30min)
C-peptide Incremental Area Under the Curve (IAUC) from 0 to 30 min
Time frame: From 0 to 30 minutes after glucose ingestion during each experimental visit
Hormonal response parameters for C-peptide during OGTT - iAUC (30-120min)
C-peptide Incremental Area Under the Curve (IAUC) from 30 to 120 min
Time frame: From 30 to 120 minutes after glucose ingestion during each experimental visit
Hormonal response parameters for C-peptide during OGTT - Δmax
The value of the maximum (peak) of the curve relative to the baseline value for C-peptide
Time frame: From 0 to 120 minutes after glucose ingestion during each experimental visit
Hormonal response parameters for C-peptide during OGTT - Time to peak
Necessary amount of time for C-peptide to reach peak in minutes
Time frame: From 0 to 120 minutes after glucose ingestion during each experimental visit
Hormonal response parameters for C-peptide during OGTT - Growth curve slope
Slope of the C-peptide growth curve from baseline
Time frame: From 0 to 120 minutes after glucose ingestion during each experimental visit
Hormonal response parameters for C-peptide during OGTT - Decay curve slope
Slope of the C-peptide decay curve from the maximum (peak)
Time frame: From 0 to 120 minutes after glucose ingestion during each experimental visit
Hormonal response parameters for GLP-1 during OGTT - iAUC (0-120min)
GLP1 Incremental Area Under the Curve (IAUC) from 0 to 120 min
Time frame: From 0 to 120 minutes after glucose ingestion during each experimental visit
Hormonal response parameters for GLP-1 during OGTT - iAUC (0-30min)
GLP-1 Incremental Area Under the Curve (IAUC) from 0 to 30 min
Time frame: From 0 to 30 minutes after glucose ingestion during each experimental visit
Hormonal response parameters for GLP-1 during OGTT - iAUC (30-120min)
GLP-1 Incremental Area Under the Curve (IAUC) from 30 to 120 min
Time frame: From 30 to 120 minutes after glucose ingestion during each experimental visit
Hormonal response parameters for GLP-1 during OGTT - Δmax
The value of the maximum (peak) of the curve relative to the baseline value for GLP-1
Time frame: From 0 to 120 minutes after glucose ingestion during each experimental visit
Hormonal response parameters for GLP-1 during OGTT - Time to peak
Necessary amount of time for GLP-1 to reach peak in minutes
Time frame: From 0 to 120 minutes after glucose ingestion during each experimental visit
Hormonal response parameters for GLP-1 during OGTT - Growth curve slope
Slope of the GLP-1 growth curve from baseline
Time frame: From 0 to 120 minutes after glucose ingestion during each experimental visit
Hormonal response parameters for GLP-1 during OGTT - Decay curve slope
Slope of the GLP-1 decay curve from the maximum (peak)
Time frame: From 0 to 120 minutes after glucose ingestion during each experimental visit
Correlation between CPIR characteristics and metabolic/hormonal responses
Correlations between CPIR features and subsequent glucose response during OGTT (including glucose iAUC 0-120 and early/late components) and hormonal quantitative/kinetic responses, including assessment of interaction with metabolic status.
Time frame: Assessed using measurements collected during each experimental visit up to 120 minutes after glucose ingestion
Participant-rated appreciation of the experimental odor
Appreciation of the experimental odor and related emotions assessed using Likert scales at the end of the odor visit, with comparison by condition and metabolic status where applicable. Exact scale range and anchor wording are not provided in the available protocol text.
Time frame: Week 2 ; Week 4
Participant-rated acceptability of the test environment - Temperature
Acceptability and appreciation of the temperature of the environment assessed using Likert scales and free-text fields. Comparison by condition and metabolic status. Scale range should be entered exactly as used in source questionnaires.
Time frame: Week 2 ; Week 4
Participant-rated acceptability of the test environment - Lighting
Acceptability and appreciation of the lighting of the environment assessed using Likert scales and free-text fields. Comparison by condition and metabolic status. Scale range should be entered exactly as used in source questionnaires.
Time frame: Week 2 ; Week 4
Participant-rated acceptability of the test environment - Sound
Acceptability and appreciation of the sound of the environment assessed using Likert scales and free-text fields. Comparison by condition and metabolic status. Scale range should be entered exactly as used in source questionnaires.
Time frame: Week 2 ; Week 4
Participant-rated acceptability of the test environment - Odor
Acceptability and appreciation of the odor of the environment assessed using Likert scales and free-text fields. Comparison by condition and metabolic status. Scale range should be entered exactly as used in source questionnaires.
Time frame: Week 2 ; Week 4
Plan to share: Undecided — No IPD sharing statement is provided in the available protocol for the moment.
No publications or documents are linked to this record.
Start is estimated for Jun 2026; primary completion for Jul 2027, 13 months later.
Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 13 months is below that.
Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.